Dose-effect relationship and long-term effects of bisoprolol in mild to moderate hypertension
- PMID: 2439780
- DOI: 10.1097/00005344-198511001-00020
Dose-effect relationship and long-term effects of bisoprolol in mild to moderate hypertension
Abstract
In an initial double-blind randomized study with three parallel groups, 48 patients, mean age 49.6 years (32-65 years), with hypertension WHO I-II, were given bisoprolol in doses of 5, 10, and 20 mg. Bisoprolol is a new beta 1-selective beta-blocking agent with a plasma half-life of 10-12 h and without intrinsic sympathomimetic activity (ISA). After the initial 8 weeks, systolic (SBP) and diastolic blood pressure (DBP) and heart rate (HR) measured at rest and during exercise 24 h after last drug intake showed a significant decrease for all three parameters in all three treatment groups. There were no differences in efficacy between the 5 and 10 mg doses of bisoprolol, whereas 20 mg was significantly more effective than both 5 mg (p less than 0.01) and 10 mg (p less than 0.05). After 10 months of treatment with dose adjustments up or down, the reduction of SBP, DBP, and HR at rest and during exercise remained unchanged. One patient had an acute myocardial infarction (AMI) and died during the study; another patient had a car accident in which he got asphyxial cerebral lesions and could not complete the study. Twelve patients spontaneously expressed side effects of the kind normally seen in treatment with beta-blocking agents. Three of them complained of cold hands and feet, and one of them was unable to complete the study. The rest of the adverse effects were mild, and 45 patients completed the long-term study. Laboratory safety tests were normal, and there were no significant changes in the lipoprotein patterns (cholesterol, HDL cholesterol, and triglycerides).(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Effects of bisoprolol on blood pressure, serum lipids and HDL-cholesterol in essential hypertension.Eur J Clin Pharmacol. 1987;32(1):77-80. doi: 10.1007/BF00609961. Eur J Clin Pharmacol. 1987. PMID: 2884116
-
Long-term effects of bisoprolol on blood pressure, serum lipids, and HDL-cholesterol in patients with essential hypertension.J Cardiovasc Pharmacol. 1986;8 Suppl 11:S134-8. doi: 10.1097/00005344-198511001-00024. J Cardiovasc Pharmacol. 1986. PMID: 2439784
-
Antihypertensive effects of bisoprolol during once daily administration in patients with essential hypertension. A dose-ranging study with parallel groups.Eur J Clin Pharmacol. 1986;29(5):517-21. doi: 10.1007/BF00635886. Eur J Clin Pharmacol. 1986. PMID: 2869951 Clinical Trial.
-
Bisoprolol: a new beta-adrenoceptor blocking drug.Eur Heart J. 1987 Dec;8 Suppl M:121-9. doi: 10.1093/eurheartj/8.suppl_m.121. Eur Heart J. 1987. PMID: 2897295 Review.
-
Overview of clinical safety and efficacy of tertatolol.Cardiology. 1993;83 Suppl 1:41-50. doi: 10.1159/000176009. Cardiology. 1993. PMID: 7903214 Review.
Cited by
-
Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.Drugs. 1988 Sep;36(3):256-85. doi: 10.2165/00003495-198836030-00002. Drugs. 1988. PMID: 2903820 Review.
-
Newer beta blockers and the treatment of hypertension.Cardiovasc Drugs Ther. 1991 Jun;5(3):577-87. doi: 10.1007/BF03029727. Cardiovasc Drugs Ther. 1991. PMID: 1678961 Review.
-
Cardioprotective and antiarrhythmic effects of beta-blockers, propranolol, bisoprolol, and nipradilol in a canine model of regional ischemia.Heart Vessels. 1989;5(1):10-6. doi: 10.1007/BF02058353. Heart Vessels. 1989. PMID: 2573596
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical